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Abstract Regulatory domain elements of the non-calcium-
dependent protein kinase C8 (nPKC5), including either or both 
of the cysteine-rich regions Cysl(5) and Cys2(5), were expressed 
as fusion proteins with glutathione-S-transferase and character-
ized using liposomal or mixed micellar phorbol ester binding 
assays. Fusion proteins containing Cys2(5) bound phorbol-12,13-
dibutyrate (PDBu) efficiently in the assay employing phospha-
tidylserine (PS) vesicles, while no significant binding was seen for 
proteins containing only Cvsl(6). Likewise, in mixed micellar 
assays, fusion proteins with Cys2(5) bound PDBu with high 
affinity (ΚΛ: 1Φ-37 nM) and to significant stoichiometric levels 
(0.23-0.66 mol/mol), but no binding could be detected for 
proteins with Cysl(5) only. The PS dependence of PDBu binding 
to Cys2(6) was highly cooperative with Hill numbers lying in the 
range of 2.5-5.2. These results demonstrate the presence of 
striking functional differences between the cysteine-rich regions 
of nPKC5 and the calcium-dependent isoform, cPKOy, where 
both cysteine-rich regions represent functional PDBu binding 
elements. 
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1. Introduction 
Protein kinase C (PKC) is a family of at least 11 serine/ 
threonine kinases critically implicated in the control of many 
cellular processes including important growth-related events 
like proliferation, differentiation or cell transformation. 
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Abbreviations: aPKC, atypical PKC; AT, antisense; Cl, first con-
served region of PKC; C2, second conserved region of cPKC; C6H2, 
six conserved cysteines and two conserved histidines of cysteine-rich 
regions; cPKC, calcium-dependent PKC; Cysl, first cysteine-rich 
region of PKC; Cys2, second cysteine-rich region of PKC; DAG, 
diacylglycerol; EGTA, ethyleneglycol-bis-(2-aminoethyl)-tetraacetic 
acid; GST, glutathione-S-transferase; GST-PKC5, COOH-terminal 
fusion proteins of GST with regulatory domain elements of PKC5 (see 
Fig. 1); HEPES, iV-[2-hydroxyethyl]piperazine-7Y'-[2-ethanesulfonic 
acid]; IPTG, isopropyl-l-thio-p-D-galactopyranoside; nPKC, non-
calcium-dependent PKC; PKC, protein kinase C; PDBu, 4β-ρ1ΐ0Γ-
bol-12,13-dibutyrate; PMA, phorbol 12-myristate 13-acetate; PS, 1,2-
dioleoyl-L-3-phosphatidyl-L-serine; SDS-PAGE, sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis; SN, sense; VI, first variable 
region of PKC; V2, second variable region of PKC; ψ, pseudosub-
strate region of PKC 
PKCs are divided into three groups: the calcium-dependent 
cPKCs (a, βι, βpi, γ), non-calcium-dependent nPKCs (δ, ε, 
r|(L), Θ), atypical aPKCs (ζ, λ/t), and the novel atypical 
ΡΚΟμ. All in common is the presence of an NH2-terminal 
regulatory domain that maintains the kinase in an inactive 
state in the absence of stimuli [1-5]. 
A physiologically relevant mechanism of cPKC and nPKC 
activation involves multiple simultaneous interactions of the 
regulatory domain with the essential acidic phospholipid co-
factor phosphatidylserine (PS) and the neutral lipid activator 
diacylglycerol (DAG). These interactions induce conforma-
tional changes required to release autoinhibition of catalytic 
domain activity [3-6]. cPKCs and nPKCs are also activated 
by phorbol esters which, in the presence of PS, bind to a site 
similar if not identical to that occupied by DAG [5,7-10]. 
aPKCs, by contrast, neither bind to nor are activated by 
either phorbol esters or DAGs [5,11-13]. 
A hallmark of all PKC isoforms characterized so far is the 
presence of 50-51 amino acid cysteine-rich regions with the 
general formula H-X12 C X2 C Xn C X2 C X4 H X2 C 
X7-C, where C = cysteine, H = histidine, X = variable amino 
acids and n= 13-14 for PKCs [11,14]. The six conserved cys-
teines and two conserved histidines (CeH2) found in all cys-
teine-rich regions are required for coordination of two atoms 
of zinc and, with the exception of the most COOH-terminal 
conserved cysteine, are crucial for these sequence elements to 
function as phorbol ester binding sites [15,16]. In addition to 
the C6H2 consensus, a conserved proline residue at position 
11 has been identified in cysteine-rich regions of cPKCs and 
nPKCs, which is altered to glycine in aPKCζ. Upon mutation 
of this conserved proline to glycine in the second cysteine-rich 
region of PKC6, phorbol ester binding is abolished [15]. This 
result provides a rationale to understand the highly distinct 
regulatory properties of aPKCs, but most of all underscores 
the importance of cysteine-rich regions as key distinguishing 
elements between PKC isoforms. 
Previous studies characterizing lipid interactions with the 
regulatory domain elements of PKCy indicated that Cysl(y) 
and Cys2(y) are functionally indistinguishable when expressed 
individually as COOH-terminal fusion proteins with glu-
tathione-S-transferase (GST). However, when together as a 
GST-CyslCys2(y) fusion protein, two binding sites with dis-
tinct PDBu binding affinities were detected in the presence of 
calcium, one of which bound PDBu with an affinity compar-
able to that of intact PKCy [17]. The inference that only one 
of the two cysteine-rich regions present in cPKCs is ultimately 
responsible for phorbol ester- or DAG-dependent PKC acti-
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vation is entirely consistent with data from the literature 
showing that binding of either one molecule of phorbol ester 
or D A G is sufficient for complete P K C activation [17-19]. 
cPKCs contain a C2 region COOH-terminal to the second 
cysteine-rich region (Cys2), which is implicated in mediating 
calcium-dependent activation of these isoforms [20-22] and 
directly coordinates two calcium atoms between conserved 
aspartic acid residues [23]. In nPKCs an element homologous 
to the C2 region, but lacking the aspartic acid residues re-
quired for calcium binding, is found NH2-terminal to the first 
cysteine-rich region (Cysl) [24,25]. To investigate the regula-
tion of nPKCs and identify differences between cPKCs and 
nPKCs not necessarily linked to the presence of the C2 region, 
regulatory domain elements of P K C 5 expressed as GST fusion 
proteins were purified and subsequently characterized. Here 
we show that, unlike the cysteine-rich regions of cPKCy 
[17], Cysl(5) and Cys2(6) differ very dramatically in their 
ability to bind PDBu in the presence of PS. While Cys2(5) 
was indistinguishable from the two cysteine-rich regions of 
PKCy, Cysl(5) lacked the capacity to bind PDBu, suggesting 
that Cys2(6) is the regulatory domain element responsible for 
PDBu/DAG-dependent activation of PKC5 . 
2. Materials and methods 
2.1. Materials 
Heat-stable Taq polymerase was from Perkin Elmer, the Geneclean 
kit from BiolOl, 4P-phorbol-12,13-dibutyrate and glutathione agarose 
from Sigma, 20-[3H]-4P-phorbol-12,13-dibutyrate from DuPont NEN, 
the l,2-dioleoyl-L-3-phosphatidyl-L-serine from Avanti Polar Lipids 
Inc., Triton X-100 from Pierce Chemical Co., the gel filtration matrix 
Sephacryl S-200-HR from Pharmacia Biotech, and prestained molec-
ular size standards were from BioRad. All other reagents were of the 
highest quality available. 
2.2. Expression of GST-PKC& fusion proteins 
To obtain large quantities of protein for characterization, PKC8 
regulatory domain elements were expressed in Escherichia coli as 
COOH-terminal fusion proteins with GST as described [26]. Briefly, 
elements of the regulatory domain of rat PKC5 [21] were amplified by 
the polymerase chain reaction (PCR) with 5' end primers (SN) con-
taining BamHI and Bglll restriction sites and 3' end primers (AT) 
containing Kpnl and EcoRl restriction sites. The following list shows 
all primers used in PCR experiments with their respective abbrevia-
tions indicating either the first (SN primers at 5' end) or last amino 
acid residue (AT primers at 3' end) of PKC8 present with the restric-
tion sites underlined: 
delta/A2 (SN): aa gga tec aga tct gca ccg ttc ctg eg 
delta/Q150 (SN): cgc cgt gga tec aga tct cag gec aag att 
delta/Q221 (SN): age egg gga tec aga tct cag aaa gaa cgc 
delta/K157 (AT): t ggc gat gaa ttc ggt ace ctt gat gta gtg 
delta/R216 (AT): t ctg gaa ttc ggt ace ccg get att gg 
delta/T295 (AT): tgg ctt ccg gaa ttc ggt ace ggt cac ttg gtt c 
delta/T331 (AT): at ctt gaa ttc ggt ace gtt gtt gtc tgg gat 
DNA amplification was carried out for 35 cycles, each at 94°C for 
1 min, 55°C for 1 min, and 72°C for 2 min. Amplification products 
were digested with BamHl/EcoRl, analyzed on 2% agarose gels, iso-
lated using Geneclean®1 (from BiolOl) following standard protocols 
provided by the manufacturer, and ligated into BamHl/EcoRl double-
digested pGEX2T plasmid (Pharmacia Biotech). Following ligation, 
E. coli XL IB (Stratagene) were transformed with the plasmids by 
electroporation (2.5 kV for 4-5 s). Positive clones were initially se-
lected by restriction analysis and subsequently confirmed by sequenc-
ing. For all plasmids encoding Cys2(5), a single base change in com-
parison to the originally published sequence [21] was detected leading 
to a replacement of threonine by serine at position 249 of PKC5. 
Fusion proteins were expressed in E. coli at 20°C for 16 h after addi-
tion of IPTG to a final concentration of 0.2 mM as described [26]. 
Cells were harvested by centrifugation and cell pellets were stored 
frozen at -20°C. 
2.3. Purification of GST fusion proteins 
GST fusion proteins were purified from E. coli cell lysates in the 
presence of protease inhibitors by affinity chromatography using glu-
tathione-agarose (Sigma) and subsequently stored at —20°C in the 
elution buffer [26]. Proteins were quantitated by the Amido Black 
dye binding assay [27] using fatty acid-free bovine serum albumin as 
a standard. 
2.4. [3H]PDBu-binding assay 
PDBu binding was measured either in the vesicle assay in the pres-
ence of 100 nM [3H]PDBu and 1 mM CaCl2 [10,28] or in the mixed 
micellar assay as described [17,19]. To determine PDBu binding in 
mixed micelle experiments, the [3H]PDBu concentration in the reac-
tion mixture was varied from 10 to 200 nM in the presence of either 
1 mM CaCl2 or 1 mM EGTA and 30 mol% PS. For measurements of 
PS concentration-dependent PDBu binding, the PDBu concentration 
was held constant at 50 nM and the PS concentration in mixed mi-
celles was varied from 4 to 30 mol% in the presence of either 1 mM 
CaCl2, 1 mM MgCl2 or 1 mM EGTA. Protein-bound and free PDBu 
was separated by gel filtration in Sephacryl S-200-HR columns (bed 
volume: 2 ml). 
2.5. Data analysis 
PDBu concentration-dependent PDBu binding was evaluated by 
Scatchard analysis as described [10,17]. PS concentration-dependent 
PDBu binding was analyzed by a non-linear least squares to fit to a 
modified Hill equation as described [10,17]: 
\ f c n n+x n V 
where y is the amount of PDBu binding measured, a the maximum 
PDBu binding value, x the concentration of PS, k the concentration 
of PS resulting in half-maximal binding, and «H the Hill coefficient. 
2.6. Analysis by SDS-PAGEIimmunoblots 
Fusion proteins were characterized by SDS-PAGE on 10% minigels 
(BioRad) and identified with an anti-GST antibody [17] after transfer 
to nitrocellulose [29]. 
3. Results 
3.1. Purification and characterization of GST-PKCh fusion 
proteins 
In order to gain deeper insight into lipid interactions in the 
regulatory domain of n P K C 5 relevant to activation, different 
elements (see Fig. 1) were expressed in E. coli as G S T fusion 
proteins and purified following protocols established for 
ΡΚΟγ [10,17,26]. In contrast to PKCy [17,26] all GST-PKC5 
fusion proteins listed (Fig. 1) were readily expressed as soluble 
proteins without severe degradation in the strain XL1B. Pur-
ification by affinity chromatography on glutathione agarose 
yielded in several cases homogeneous protein preparations 
as judged by Coomassie Blue staining (Fig. 2A; lanes 1, 2, 
5 and 8). For other fusion proteins, multiple bands were visi-
ble (Fig. 2A; lanes 3, 4, 6, 7 and 9), but also here a major 
band of the anticipated molecular mass was clearly identifi-
able (see arrows). The less abundant protein species in these 
preparations generally migrated with somewhat lower appar-
ent molecular weight compared to the major species, suggest-
ing that the former might represent degradation products of 
the latter. 
To further confirm the identity of the expressed and pur-
ified fusion proteins, these were transferred to nitrocellulose 
and probed with an anti-GST antibody (Fig. 2B). The major 
bands visible after Coomassie Blue staining, which migrated 
with apparent molecular masses anticipated for the respective 
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GST fusion protein 
(Code NrVname) 
1 / GST-V1 
2/GST-V1Cys1 
3/GST-V1Cys1Cys2 
4 / GST-V1 Cys1 Cys2hinge 
5 / GST-Cys1 
6/GST-Cys1Cys2 
7 / GST-Cy1 Cys2hinge 
8/GST-Cys2 
9 / GST-Cys2hinge 
PKC5 
amino acids 
present 
2 - 157 
2 - 216 
2 - 295 
2 - 331 
150- 216 
150- 295 
150- 331 
221 - 295 
221- 331 
Primers used for PCR 
(sense/antisense) 
A2(SN)/K157(AT) 
A2(SN)/R216(AT) 
A2(SN)/T295(AT) 
A2(SN)/T331(AT) 
Q150(SN)/R216(AT) 
Q150(SN)/T295(AT) 
Q150(SN)/T331(AT) 
Q221(SN)/T295(AT) 
Q221(SN)/T331(AT) 
Predicted 
Mr (x 10-3) 
of fusion 
protein 
45.3 
52.0 
61.1 
65.0 
35.2 
44.3 
48.1 
36.1 
40.0 
Elements of PKC6 regulatory domain 
vi : c i : V2 
>i;Cys1 Cys2 hinge 
Fig. 1. Expression of PKC8 regulatory domain elements as GST fusion proteins. GST fusion proteins with PKC8 regulatory domain elements 
were generated by PCR using the indicated combinations of sense (SN) and antisense (AT) primers, followed by ligation into pGEX2T, and 
subsequent expression in the E. coli strain XL1B (see Section 2). Amino acids of PKC8 present and predicted molecular weights (Mr) of the re-
spective GST-PKC5 fusion proteins are shown. Regulatory domain elements of PKC5 present in the respective fusion proteins are illustrated 
schematically: VI, first variable region containing the pseudosubstrate region (ψ); Cl, first conserved region with the two cysteine-rich regions 
(Cysl and Cys2); V2, second variable region or hinge region. 
fusion proteins (Fig. 1), were also detected by this antibody 
(Fig. 2A,B; see arrows). In those preparations where multiple 
bands were visible after Coomassie Blue staining (Fig. 2A; 
lanes 3, 4, 6, 7 and 9), corresponding additional bands migrat-
ing ahead of the major band, were also detected by the anti-
body, supporting the notion that apparent impurity of the 
preparations was predominantly due to degradation of the 
respective fusion protein. However, it is important to note 
that degradation affected mainly those proteins containing 
both cysteine-rich regions (Fig. 2; lanes 3, 4, 6 and 7) or 
Cys2(6) together with the hinge region (Fig. 2; lane 9) but 
not those with VlCysl(6), Cysl(5) or Cys2(5) (Fig. 2; lanes 2, 
5 and 8). Protease cleavage sites are present within the hinge 
regions of PKCs [30,31] and thus fusion proteins containing 
this element (Fig. 2; lanes 4, 7 and 9) are expected to be more 
susceptible to degradation. 
while no significant binding could be detected with Cysl(6) 
alone (Fig. 4C,D). 
All purified fusion proteins (Figs. 1 and 2) were character-
ized in the manner shown in Fig. 4, either in the presence of 
3.2. PDBu binding in the vesicle assay 
In the presence of PS liposomes, all fusion proteins contain-
ing either Cys2(5) alone (Fig. 3; fusion proteins 8 and 9) or 
Cysl(5) and Cys2(5) together (Fig. 3; fusion proteins 3, 4, 6 
and 7) readily bound PDBu, while those with only Cysl(6) 
(Fig. 3; fusion proteins 2 and 5) were essentially non-func-
tional, as was also a fusion protein lacking any of the cys-
teine-rich regions (Fig. 3; fusion protein 1). Highest levels of 
binding, comparable to values previously reported for GST-
PKCy fusion proteins [17,26] were measured for GST-PKC5 
fusion proteins containing both cysteine-rich regions, despite 
more apparent proteolytic degradation in these preparations 
(Fig. 2; lanes 3, 4, 6 and 7). 
3.3. PDBu binding in the mixed micellar assay: PDBu 
concentration dependence 
To investigate these differences in greater detail, PDBu 
binding was also measured using the mixed micellar assay, 
which permits the determination of binding affinities and stoi-
chiometries (Fig. 4 and Table 1). As anticipated based upon 
the above results, the fusion proteins GST-Cys2(5) (Fig. 
4A,B) or GST-CyslCys2(5) (Fig. 4E,F) bound PDBu with 
high affinity (19.1 ±2.6 nM and 18.2 ±3.3 nM, respectively) 
and comparable stoichiometries (0.37 ±0.05 and 0.49 ±0.09), 
Fig. 2. Characterization of GST-PKC8 fusion proteins. Affinity-pur-
ified GST-PKC5 fusion proteins (3 μg/lane) resolved by SDS-PAGE 
on 10% gels were stained with Coomassie Blue (A) or transferred to 
nitrocellulose, where they were probed with a polyclonal rabbit anti-
GST antibody (B): lane 1, GST-V1; lane 2, GST-VlCysl; lane 3, 
GST-VlCyslCys2; lane 4, GST-VlCyslCys2hinge; lane 5, GST-
Cysl; lane 6, GST-CyslCys2; lane 7, GST-CyslCys2hinge; lane 8, 
GST-Cys2; lane 9, GST-Cys2hinge. Bands corresponding in size to 
the anticipated Mr values of the GST-fusion proteins are marked 
with an arrow. Values of prestained molecular weight markers are 
indicated on the left. Additionally the migration position of GST 
alone (27.5 kDa) is indicated. 
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Fig. 3. Comparison of PDBu binding of GST-PKC8 fusion proteins 
in the vesicle assay. [3H]PDBu binding of PKC5 fusion proteins 
(mmol PDBu/mol protein) is depicted. Errors indicated are standard 
deviations of at least three independent experiments. Standard de-
viations below the threshold values of 5 are not visible on the 
graph. Fusion proteins are abbreviated by code numbers shown in 
Fig. 1. Results are grouped according to the presence of cysteine-
rich regions: none, fusion proteins lacking cysteine-rich regions; 
Cysl, fusion proteins with only Cysl; Cys2, fusion proteins with 
only Cys2; Cysl and Cys2, fusion proteins with both cysteine-rich 
regions. PDBu binding values (mmol PDBu/mol protein) for fusion 
proteins, listed with the respective code numbers in brackets, are as 
follows: VI (1) 0; VICysl (2) 5 ±5; Cysl (5) 9±6; Cys2 (8) 23±6; 
Cys2hinge (9) 40±2; VlCyslCys2 (3) 77 ±5; VlCyslCys2hinge (4) 
99±1; CyslCys2 (6) 65±21; CyslCys2hinge (7) 65±11. 
1 mM CaCi2 or 1 mM EGTA. As suspected for regulatory 
domain elements of an nPKC, where calcium is not required 
for activation, no significant differences in either stoichiome-
try (averaged values: 0.51 ±0.10 and 0.42 ±0.25, respectively) 
or affinity (averaged values: 24.3 ±4.5 nM and 20.6 ± 8.6 nM, 
respectively) of binding were noticeable. Binding was seen 
with fusion proteins containing the Cys2(5) region (Table 1, 
fusion proteins 3, 4, 6, 7, 8, 9) but not with those in which 
only Cysl(5) was present (Table 1, fusion proteins 2 and 5). 
Amongst Cys2(5)-containing proteins no distinction was pos-
sible between those containing only Cys2(6) (fusion proteins 8, 
9: averaged affinity, 19.5 ±4.4; stoichiometry, 0.42 ±0.10) and 
those with both Cysl(6) and Cys2(8) (fusion proteins 3, 4, 6, 
7: averaged affinity, 23.8 ±7.7; stoichiometry, 0.49 ±0.23), 
suggesting that Cys2(5) represents the element in the regula-
tory domain of PKC5 exclusively responsible for PDBu bind-
ing and, by inference, DAG-dependent PKC6 activation. 
3.4. PDBu binding in the mixed micellar assay: PS 
concentration dependence 
Experiments assessing the dependence of PDBu binding on 
the PS concentration in the presence of 1 mM CaCl2, 1 mM 
MgCl2 or 1 mM EGTA are shown for GST-Cys2(6)hinge 
(Fig. 5). Values for the PS concentration required for half 
maximal binding varied depending on the conditions, being 
similar in the presence of 1 mM CaCk or 1 mM EGTA 
(13.5 ±1.7 and 11.3 ±0.6 mol%, respectively), but slightly 
higher in the presence of magnesium (17.0 ±6.1 mol%), where 
also total PDBu binding doubled. An increase in PDBu bind-
ing in the presence of magnesium, but without alteration in 
the PS concentration required for half maximal binding was 
reported for GST-PKCy fusion proteins [17]. Alternatively, 
the Hill numbers (nH) calculated for PS concentration-depend-
ent PDBu binding are similar in the presence of 1 mM CaCb 
or 1 mM MgCl2 («H = 2.5 ± 0.5 and 2.6 ± 1.3, respectively), but 
somewhat higher in the presence of 1 mM EGTA 
(«H = 5.2± 1.4), following the trend previously seen for cys-
teine-rich regions of cPKCy [17], although values obtained 
for Cys2hinge of PKC6 under the different conditions are 
slightly lower. 
4. Discussion 
A common feature of cPKCs and nPKCs is their activation 
by DAGs and phorbol esters such as phorbol 12-myristate 13-
acetate (PMA) or PDBu in the presence of PS, as well as the 
presence of two cysteine-rich regions in tandem within the 
regulatory domain. While cysteine-rich regions are essential 
for lipid-dependent PKC activation, recent experiments in 
particular with cPKCs indicate that they are not functionally 
equivalent in the context of the intact regulatory domain. For 
instance, two distinct phorbol ester binding sites have been 
detected in PKCoc that differ in their PDBu binding affinity 
[11] and their ability to bind the fluorescent phorbol ester 
analog sapintoxin-D [32]. Also, cysteine-rich regions of 
Table 1 
Summary of PDBu binding values determined in the mixed micellar assay for GST-PKC5 fusion proteins 
GST-PKC5 fusion protein 
Code no. 
1 
5 
2 
3 
4 
6 
7 
8 
9 
Average 
Name 
VI 
Cysl 
VICysl 
VlCyslCys2 
VlCyslCys2hinge 
CyslCys2 
CyslCys2hinge 
Cys2 
Cys2hinge 
+Ca 
Kd 
(nM±SD) 
nb 
nb 
nb 
28.6 ±4.7 
28.3 ±0.7 
18.2±3.3 
26.7 ±5.9 
19.1 ±2.6 
25.0±1.5 
24.3 ±4.5 
Stoichiometry 
(mol/mol ±SD) 
0.41 ±0.16 
0.57 ±0.01 
0.49 ±0.09 
0.66±0.15 
0.37 ±0.05 
0.56 ±0.03 
0.51 ±0.10 
+EGTA 
Kd 
(nM±SD) 
nb 
nb 
nb 
14.3 ±2.4 
16.3 ±4.5 
21.3±4.8 
37.0 ±12.0 
14.3 ±1.8 
nd 
20.6 ±8.6 
Stoichiometry 
(mol/mol ±SD) 
0.23 ± 0.04 
0.38 ±0.10 
0.25 ± 0.06 
0.92 ±0.29 
0.33 ±0.04 
nd 
0.42 ±0.25 
PDBu binding was measured in the presence of either 1 mM CaCl2 (Ca) or 1 mM EGTA (EGTA) and Triton X-100 mixed micelles containing 30 
mol% PS. PDBu binding affinities (Kd, nM) and stoichiometries (n, mol/mol protein) were calculated by Scatchard analysis. Errors indicated are 
equivalent to the standard deviations (SD) obtained by regression analysis. Fusion proteins lacking Cys2 did not bind PDBu (nb). Average values 
for PDBu binding affinity and stoichiometry of all fusion proteins containing Cys2 were 24.3 ±4.5 nM, « = 0.51 ±0.10 mol/mol (Ca), and 20.6 ±9.6 
nM, n = 0.42 ±0.28 mol/mol (EGTA). For GST fusion proteins having both cysteine-rich regions (VlCyslCys2, VlCyslCys2hinge, CyslCys2, 
CyslCys2hinge), the average values for PDBu binding affinity and stoichiometry were 23.8 ±7.7 nM and n = 0.49 ±0.23 mol/mol. For Cys2 and 
Cys2hinge, averaged PDBu affinity and stoichiometry values were 19.5 ±4.4 nM and « = 0.42 ±0.10 mol/mol. 
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Fig. 4. Comparison of PDBu binding of GST-PKC8 fusion proteins GST-Cysl, GST-Cys2, and GST-CyslCys2 in the mixed micellar assay. 
PDBu binding of GST-Cys2 (A,B), GST-Cysl (C,D), or GST-CyslCys2 (E, F) were measured in the presence of 1 mM CaCl2 and Triton X-
100 mixed micelles containing 30 mol% PS. [3H]PDBu binding is depicted as a function of the PDBu concentration present (A,C and E) or the 
corresponding Scatchard plots are shown (B,D and F). Binding affinity (Kd) as well as the stoichiometry (n) for GST-Cys2 (Kd = 19.1 ±2.6 nM, 
» = 0.37 ±0.05 mol/mol) and GST-CyslCys2 (Kd = 18.2 ±3.3 nM, n = 0.49 ±0.09 mol/mol) were determined by regression analysis. 
PKCy which are functionally equivalent when expressed indi-
vidually, behaved very differently in a GST-Cysl Cys2y fusion 
protein [17]. Finally, one molecule of either phorbol ester or 
DAG is sufficient for maximum PKC activation and binding 
stoichiometries for either PDBu or DAG are around one 
[7,18,19]. Taken together, these results indicate that the con-
text in which a cysteine-rich region is present within the reg-
ulatory domain of cPKCs dictates whether it directly mediates 
binding of either DAGs or phorbol esters critical for activa-
tion. 
In the work presented here, we have characterized GST-
PKC5 fusion proteins, as previously described for PKCy, with 
particular emphasis on identifying differences between cys-
teine-rich regions. In the vesicle assay, significant PDBu bind-
ing was seen with any fusion protein containing Cys2(5), but 
not with those in which only Cysl(5) was present (Fig. 3), 
although the quality of non-functional Cysl(6) containing fu-
sion proteins was comparable to those containing Cys2(6) (see 
SDS-PAGE analysis in Fig. 2). Elevated PDBu binding in 
fusion proteins with both cysteine-rich regions in the vesicle 
assay (Fig. 3) indicated that Cysl(6) might promote PDBu 
binding in fusion proteins containing both cysteine-rich re-
gions. Measurements in the mixed micellar assay clearly con-
firmed that the presence of Cys2(5) was essential for high-
affinity PDBu binding (Fig. 4). Furthermore, no significant 
differences in either PDBu binding affinity or stoichiometry 
were apparent between any of the Cys2(6)-containing fusion 
proteins (Table 1). Thus, the presence of Cysl(5) did not 
facilitate PDBu binding to Cys2(5)-containing fusion proteins 
in the mixed micellar assay by any of these criteria. 
PS concentration dependence of PKC activation and PDBu 
binding is highly cooperative for cPKCs with Hill numbers 
ranging from 4 to 11, indicative of multiple PS interactions 
being critical for activation [18,33,34]. Experiments analyzing 
cysteine-rich regions indicate that for PKCy the PS binding 
sites critical for activation are present within an individual 
cysteine-rich region. PS concentration-dependent PDBu bind-
ing experiments with GST-Cys2(6)hinge (Fig. 5) showed that 
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Fig. 5. PS concentration dependent PDBu binding of GST-Cys2-
hinge in the mixed micellar assay. [3H]PDBu binding is shown as a 
function of the PS concentration (4-30 mol%) in the presence of 
1 mM CaCl2 ( · ) , 1 mM MgCl2 ( A ) , or 1 mM EGTA (■). Binding 
data were analyzed by non-linear regression analysis and curves rep-
resenting best fits are shown. PS concentrations for half-maximal 
binding as well as Hill numbers («H) calculated for these curves are 
as follows: 13.5±1.7 mol% and «H = 2.5 + 0.5 (Ca); 11.3±0.6 mol% 
and «H = 5.2+1.4 (EGTA); 17.0 + 6.1 mol% and »H = 2.6+1.3 (Mg). 
PDBu binding was also highly cooperative, yielding Hill coef-
ficients ( « H - 2 . 5 - 5 . 2 ) and PS concentrations for half maximal 
binding (11.3-17 mol%) comparable to those reported for 
both Cysl(y) and Cys2(y) [17]. Analysis of GST-CyslCys2(5) 
in the same manner yielded similar results (data not shown) 
providing additional evidence for the absence in Cysl(5) of 
lipid interactions sites critical for PDBu binding. 
A possible concern regarding these experiments is that 
PDBu binding stoichiometries for Cys2(5) containing fusion 
proteins were significantly lower than 1, suggesting that, 
al though soluble, fusion proteins might not necessarily be 
functional. In this case, the inability of Cysl(6) to bind phor-
bol esters with detectable affinity could reflect a problem of 
Cysl(8) folding related to the expression system rather than a 
property inherent to this particular cysteine-rich region, and 
thus also to PKC(6). Here, however, two points are worth 
noting. First, binding stoichiometries for Cys2(5) are higher, 
on an average, than those values reported for bo th cysteine-
rich regions of PKCy [17,26]. Second, PDBu binding stoichi-
ometries are generally lower than one. Even with purified 
P K C (rat brain or recombinant), where PDBu binding affin-
ities are an order of magnitude higher, stoichiometries de-
tected may vary considerably depending on the preparation 
and the assay conditions employed, generally lying anywhere 
between 0.5 and 1.0 for recombinant P K C [17] and sometimes 
even lower for P K C purified from rat brain (A. Quest, un-
published data) . Such variations may be attributed to differ-
ences in enzyme source and preparation, as well as the fact 
that phorbol ester binding is not entirely irreversible [17]. 
PDBu binding stoichiometries can vary somewhat in the 
mixed micelle assay depending upon the affinity, as is il-
lustrated by results obtained with recombinant PKCy in the 
presence or absence of calcium, where PDBu binding affinities 
vary between 3 and 30 n M and binding stoichiometries 
roughly between 1.0 and 0.6, respectively, for comparable 
P K C preparations [17]. Hence, PDBu binding stoichiometries 
determined for fusion proteins containing Cys2(5) correspond 
to values that might be expected based on the PDBu binding 
affinities determined for these proteins, indicating that the 
majority of soluble, purified Cys2(8)-containing fusion pro-
teins do represent functional PDBu binding sites. Taken to-
gether, therefore, our results strongly suggest that the inability 
of Cysl(8) to bind PDBu represents a property inherent to 
this particular cysteine-rich motif. 
In summary, the results presented here highlight a further 
striking difference in the regulatory domain between cPKCs 
and nPKCs, in addition to the presence or absence of a C2 
region. While Cys2(5) is a functional PDBu binding site, with 
properties very similar to those reported for both cysteine-rich 
regions of PKCy, Cysl(8) is essentially non-functional in this 
respect. Thus, Cys2(6) most likely represents the region in 
P K C 5 responsible for phorbol ester- and DAG-dependent ac-
tivation. Studies are currently on the way in our laboratory to 
identify alternative roles for Cysl(5) in P K C 5 regulation. 
The above conclusion is corroborated in a recent report by 
Blumberg and coworkers using a different approach. Con-
served prolines [15] in cysteine-rich regions of P K C 5 were 
converted to glycine and the ability of resulting P K C 5 mu-
tants to bind P M A was assessed after expression in N I H 3 T 3 
cells. Mutat ions in either Cys2(5) alone or both Cysl(5) and 
Cys2(6), but not Cysl(5) alone, reduced PMA-induced mem-
brane translocation of P K C 6 [35]. 
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